MeSH term
Frequency | Condition_Probility | Adult | 9 | 0.0 |
Humans | 64 | 0.0 |
Male | 19 | 0.0 |
Middle Aged | 3 | 0.0 |
Amino Acid Sequence | 15 | 0.0 |
Animals | 44 | 0.0 |
Blotting, Western | 2 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
Potassium Channels, Voltage-Gated | 46 | 83.0 |
Precipitin Tests | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Rats | 17 | 0.0 |
Research Support, Non-U.S. Gov't | 48 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Transfection | 12 | 0.0 |
Ion Channels/*genetics/metabolism | 2 | 25.0 |
Amino Acid Substitution | 3 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Gene Expression | 3 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Microinjections | 3 | 1.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Mutation | 9 | 0.0 |
Patch-Clamp Techniques | 17 | 4.0 |
Pedigree | 12 | 0.0 |
Potassium/metabolism | 5 | 4.0 |
Potassium Channels/*genetics/metabolism | 4 | 14.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Protein Subunits | 2 | 0.0 |
Structure-Activity Relationship | 7 | 0.0 |
Xenopus | 7 | 1.0 |
Epilepsy, Benign Neonatal/genetics | 2 | 66.0 |
Immunohistochemistry | 4 | 0.0 |
Mice | 12 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Potassium Channels/genetics/*metabolism | 4 | 15.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Cell Line | 11 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
DNA Mutational Analysis | 7 | 0.0 |
Epilepsy, Benign Neonatal/*genetics/physiopathology | 2 | 100.0 |
Genetic Screening | 2 | 0.0 |
Potassium Channels/*genetics | 14 | 10.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Mutation/*genetics | 3 | 0.0 |
Electric Conductivity | 5 | 2.0 |
Electrophysiology | 8 | 1.0 |
Female | 14 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
*Mutation | 9 | 0.0 |
Potassium Channels/*genetics/physiology | 2 | 28.0 |
Syndrome | 2 | 0.0 |
Xenopus laevis | 8 | 1.0 |
Anticonvulsants/*pharmacology | 2 | 10.0 |
CHO Cells | 7 | 0.0 |
Carbamates/*pharmacology | 2 | 28.0 |
Hamsters | 7 | 0.0 |
Indoles/pharmacology | 8 | 3.0 |
Muscarinic Agonists/pharmacology | 2 | 5.0 |
Phenylenediamines/*pharmacology | 2 | 100.0 |
*Potassium Channels, Voltage-Gated | 14 | 5.0 |
Pyridines/pharmacology | 7 | 2.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Receptor, Muscarinic M1 | 2 | 8.0 |
Long QT Syndrome/genetics | 2 | 14.0 |
Potassium Channels/*drug effects/physiology | 4 | 44.0 |
Chromosome Disorders | 2 | 0.0 |
Drug Resistance | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Epilepsy/*genetics/physiopathology | 2 | 25.0 |
Gene Deletion | 2 | 0.0 |
Models, Neurological | 2 | 1.0 |
Oocytes/metabolism | 6 | 3.0 |
Point Mutation | 3 | 0.0 |
Epilepsy, Benign Neonatal/*genetics | 4 | 66.0 |
Infant | 3 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Brain/cytology/metabolism | 2 | 5.0 |
COS Cells | 3 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Neurons/cytology/drug effects/*metabolism | 2 | 5.0 |
Tetraethylammonium/pharmacology | 5 | 23.0 |
Tissue Distribution | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Phenotype | 2 | 0.0 |
Infant, Newborn | 12 | 0.0 |
Ion Channel Gating | 3 | 4.0 |
Potassium Channels/*physiology | 3 | 10.0 |
Epilepsy/*genetics | 5 | 15.0 |
Anthracenes/pharmacology | 3 | 15.0 |
Animals, Newborn/*growth & development | 2 | 18.0 |
Disease Susceptibility | 2 | 0.0 |
Mice, Knockout/*genetics/growth & development/*physiology | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Seizures/*etiology | 2 | 33.0 |
Benzimidazoles/pharmacology | 2 | 4.0 |
Kinetics | 4 | 0.0 |
Membrane Potentials/drug effects/physiology | 2 | 2.0 |
Sulfanilamides/pharmacology | 2 | 100.0 |
Electroencephalography | 3 | 1.0 |
Potassium Channels/genetics | 2 | 4.0 |
Base Sequence | 6 | 0.0 |
Exons | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Seizures/congenital/*genetics | 2 | 66.0 |
Variation (Genetics) | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Potassium Channel Blockers/pharmacology | 5 | 17.0 |
Chromosomes, Human, Pair 20 | 4 | 8.0 |
Brain/metabolism | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Oocytes | 4 | 3.0 |
Epilepsy, Generalized/*genetics | 2 | 7.0 |
Ion Channel Gating/physiology | 3 | 13.0 |
Acrylamides/*chemical synthesis/chemistry/pharmacology | 2 | 50.0 |
Morpholines/*chemical synthesis/chemistry/pharmacology | 2 | 33.0 |
Oocytes/drug effects/physiology | 2 | 14.0 |
Stereoisomerism | 3 | 0.0 |
Action Potentials | 2 | 3.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Adolescent | 3 | 0.0 |
Aged | 2 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Neurons/drug effects/*physiology | 2 | 6.0 |
Potassium/pharmacology | 2 | 3.0 |
Potassium Channels/chemistry/*physiology | 2 | 100.0 |
Hela Cells | 2 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Histamine/*pharmacology | 2 | 5.0 |
Genotype | 2 | 0.0 |
